

## Lifeline Drugs & Pharma Limited

Regd Office : 17, 3rd Floor, Zaveri Bhavan, 85/87, Old Hanuman Lane, Kalbadevi Road, Mumbai-400 002

(₹ In Lacs)

### Unaudited Financial Results for the Quarter ended December 31, 2012

Sr. No.	Particulars	Qtr ended 31.12.12	Qtr ended 30.09.12	Qtr ended 31.12.11	Nine Months ended 31.12.12	Nine Months ended 31.12.11	Year ended 31.03.12
		Un-Audited			Un-Audited		Audited
1	<b>Income from Operations</b>						
	a) Net Sales/Income from Operations	-	-	-	-	-	-
	b) Other Operating Income	-	-	-	-	-	13.46
	<b>Total Income from Operations (Net)</b>	-	-	-	-	-	13.46
2	<b>Expenditure</b>						
	(a) Cost of Material Consumed	-	-	-	-	-	-
	(b) Purchases of Stock-in-trade	-	-	-	-	-	-
	(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-	-
	(d) Employees Benefit Expenses	1.12	1.02	0.52	2.72	1.48	2.30
	(e) Depreciation & Amortization Expenses	-	-	-	-	-	-
	(f) Exchange & Depository Expenses	0.87	1.98	-	2.85	4.57	-
	(g) Other Expenditure	1.56	2.24	1.64	5.44	-	6.30
	<b>Total Expenses</b>	3.55	5.24	2.16	11.01	6.05	8.59
3	<b>Profit/(Loss) from Operations before other income, finance cost and exceptional Expenses (1-2)</b>	(3.55)	(5.24)	(2.16)	(11.01)	(6.05)	4.87
4	Other Income/(Loss)	8.68	10.12	3.02	25.18	9.58	-
5	<b>Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)</b>	5.13	4.88	0.86	14.17	3.53	4.87
6	Finance Costs	-	-	-	-	-	-
7	<b>Profit/(Loss) from ordinary activities after finance cost but before exceptional items (3+4)</b>	5.13	4.88	0.86	14.17	3.53	4.87
8	Exceptional Items	-	-	-	-	-	-
9	<b>Profit(+)/Loss(-) from ordinary activities before Tax (7-8)</b>	5.13	4.88	0.86	14.17	3.53	4.87
10	Tax Expenses	-	-	-	-	-	1.65
11	<b>Net Profit (+)/Loss(-) from ordinary activities after tax (9-10)</b>	5.13	4.88	0.86	14.17	3.53	3.22
12	Extra Ordinary Items (Net of Tax Expense of Rs. Lac)	-	-	-	-	-	-
13	<b>Net Profit (+)/Loss(-) for the period (11-12)</b>	5.13	4.88	0.86	14.17	3.53	3.22
14	Share of Profit/(Loss) of Associates*	-	-	-	-	-	-
15	Minority Interest*	-	-	-	-	-	-
16	<b>Net Profit (+)/Loss(-) after tax, minority interest and Share of Profit / (Loss) of Associates (13-14-15)</b>	5.13	4.88	0.86	14.17	3.53	3.22
17	Paid-up Equity Share Capital (Face Value of Rs. 10/- each)	233.60	120.00	24.00	233.60	24.00	24.00
18	Reserves excluding revaluation Reserves as per last Balance Sheet	-	-	-	-	-	113.19
	<b>Earning Per Share (before extra-ordinary items) of Rs. 10/- each (not annualized)</b>						
19	(i) a) Basic	0.22	0.41	0.36	0.61	1.47	1.34
	b) Diluted	0.22	0.41	0.36	0.61	1.47	1.34
19	<b>Earning Per Share (after extra-ordinary items) of Rs. 10/- each (not annualized)</b>						
	(ii) a) Basic	0.22	0.41	0.36	0.61	1.47	1.34
	b) Diluted	0.22	0.41	0.36	0.61	1.47	1.34
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>						
	Public Shareholding						
	- Number of Shares	2,333,500	2,333,500	138,790	2,333,500	138,790	138,790
	- Percentage of Share Holding	99.89	194.46	57.83	99.89	57.83	57.83
18	Promoter and Promoter Group Shareholding						
	a) Pledged/Encumbered	-	-	-	-	-	-
	- Number of Shares	-	-	-	-	-	-
	- Percentage of Shares (as a % of the total Shareholding of Promoter and Promoter Group)	-	-	-	-	-	-
	- Percentage of Shares (as a % of the total Share Capital of the Company)	-	-	-	-	-	-
	b) None-Encumbered						
	- Number of Shares	2,500	2,500	735	2,500	101,210	101,210
	- Percentage of Shares (as a % of the total Shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total Share Capital of the Company)	0.11	0.21	0.31	0.11	42.17	42.17
<b>B</b>	<b>INVESTOR COMPLAINTS</b>						
	Pending at the beginning of the Quarter	Nil	Disposed during the Quarter				Nil
	Received during the Quarter	Nil	Remaining Unresolved at the end of Quarter				Nil

**Notes :**

1. Segmental Report for the Quarter as per AS-17 of ICAI is not applicable for the Quarter.
2. Above results were reviewed by Audit Committee taken on record in Board Meeting held on February 12, 2013.
3. During the Quarter, the Company has allotted 11,36,000 Equity Shares on Preferential basis to Non-Promoter Group.
4. Provision for Taxation will be made at the end of the Financial Year.
5. The Statutory Auditors of the Company have carried out "Limited Review" of the above Financial Results.

**For Lifeline Drugs & Pharma Limited**

Sd/-

**Alok Behera**

**Managing Director**

Place : Mumbai

Date : February 12, 2013